

FORM 2B

LISTING SUMMARY

Issuer Name: XORTX Therapeutics Inc.	Listing Statement Date: November 27, 2017			
Descriptions of securities to be listed:				
Common shares				
Address: Suite 2400, 745 Thurlow Street, Vancouver, British Columbia, V6E 0C5.	Brief Description of the Issuer's Business: The Issuer is a bio-pharmaceutical company, dedicated to developing and commercialization of therapies regarding progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications and larger market type 2 diabetic nephropathy, fatty liver disease.			
Company Contact: Allen Davidoff	Description of securities outstanding: Common shares Share purchase warrants			
Phone: 403-607-2621	Symbol XRX	Type Common	Number 62,919,691	CUSIP 98420 Q108
Fax: 403-260-3501	If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event:			

E-mail: adavidoff@xortx.com			Dates of Press Release and Any Public Filings Concerning the Event: August 8, 2017	
Jurisdiction of Incorporation: British Columbia			Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): December 8, 2017	
Website: www.xortx.com				
Fiscal Year End: February 28				
Financial Information as at: December 31, 2016			Board of Directors:	
	<u>Current</u>	<u>Previous</u>	Name	Position
Current Assets	\$2,172,713	n/a	Allen Davidoff	Director and CEO
Working Capital	\$1,607,196		Alan Moore	Director
Total assets	\$2,435,945		Bruce Rowlands	Director
Long-term liabilities	\$			
Shareholders' equity	\$1,870,467			

FORM 2B – LISTING SUMMARY

January 2015

Signed at Calgary, Alberta on the 9th day of January, 2018.

XORTX Therapeutics Inc. _____
Name of Company

Allen Davidoff _____
Signing Officer

President and CEO _____
Office Held

(signed "Allen Davidoff") _____
Signature